Table 2.
Baseline demographic and clinical characteristics of pilot participants
| Number of pilot participants (N, %) | 12 (100.0) |
|---|---|
| Race (N, %) | 11 (91.7) |
| White | 0 (0) |
| African American or Black Asian | 1 (8.3) |
| Age, mean (Years, SD) | 52.7 (16.6) |
| Mean Body Surface Area (BSA) Affected With Plaque Psoriasis (%, SD) | 16.2 (6.7) |
| Mean PASI Score (N, SD) | 15.4 (2.6) |
| sPGA Score (N, %) | |
| Moderate | 8 (66.7) |
| Severe | 4 (33.3) |
| Mean PSS Score (N, SD) | 8.0 (4.0) |
| Mean DLQI Score (N, SD) | 10.8 (6.8) |
| Trial participants with at least one concomitant diagnosis (N, %) | 11 (91.7) |
| Trial participants who took non-topical psoriasis (N, %) | 6 (50.0) |
| Trial participants with at least one on-treatment concomitant medication (N, %) | 9 (75.0) |
SD=standard deviation; PASI=Psoriasis Area and Severity Index; sPGA= Static Physician’s Global Assessment; PSS=Psoriasis Symptom Scale; DLQI= Dermatology Life Quality Index.